慢性骨髓性白血病治療市場按藥物類型、給藥途徑、分銷管道和地區分類

2025 年全球慢性骨髓性白血病治療市場規模估計為 90.4 億美元，預計到 2032 年將達到 142.4 億美元，2025 年至 2032 年的複合年成長率為 6.7%。

數字。 2025年慢性骨髓性白血病治療市場佔有率（按地區）

慢性骨髓性白血病(CML) 是一種始於骨髓並導致白血球過度生成的癌症。 CML 主要是由於基因異常導致骨髓中髓系細胞不受控制地增殖並在血液中積聚而引起的。如果不及時治療，CML 會從慢性期發展到加速期，最終發展為急變期。近年來，全球慢性骨髓性白血病治療市場經歷了顯著成長，這得益於蛋白酪氨酸激酶抑制劑等創新標靶治療藥物的推出，這些藥物改善了 CML 患者的臨床結果和生活品質。

市場動態：

全球慢性骨髓性白血病治療市場受到全球範圍內慢性骨髓性白血病盛行率不斷上升以及人們對早期診斷和治療認知不斷提高的推動。此外，比傳統化療更有效、更安全的新型標靶治療藥物的開發和核准正在推動市場成長。然而，標靶治療的高價格仍然是一個重大挑戰，尤其是在對價格敏感的新興市場。從積極的一面來看，不斷成長的醫療支出和對優質藥品的需求為市場參與者提供了有利可圖的機會。此外，在預測期內，評估新治療方法的臨床試驗的合作研究可能會進一步擴大市場範圍。

本研究的主要特點

本報告對全球慢性骨髓性白血病治療市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和複合年成長率。

它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。

全球慢性骨髓性白血病治療市場的主要企業根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行分析。

研究中介紹的主要企業包括 Teva Pharmaceutical Industries Ltd.、F. Hoffmann-La Roche Ltd.、諾華公司、賽諾菲、百時美施貴寶公司、輝瑞公司、工業有限公司、信達生物製藥公司、Viatris Inc.、Lupin、Million Health Pharmaceuticals、Celon Labs 和 Fresenius Labs AGbs。

本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

全球慢性骨髓性白血病治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過用於分析全球慢性骨髓性白血病治療市場的各種策略矩陣來促進決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景
• 流行病學

第4章。慢性骨髓性白血病治療市場（按藥物類型），2020-2032 年（十億美元）

• 蛋白酪氨酸激酶抑制劑
• Imatinib（Glivac）
• Dasatinib（Sprycel）
• 尼洛替尼（Tasigna）
• Bosutinib（Bosurif）
• Ponatinib（Iclusig）
• 阿西米尼（Sembrix）
• 其他
• 抗代謝物
• 其他

第5章。慢性骨髓性白血病治療市場，依給藥途徑，2020-2032 年（十億美元）

• 口服
• 腸外
• 外用
• 其他（鼻腔等）

第6章。慢性骨髓性白血病治療市場，按分銷管道，2020-2032 年（十億美元）

• 醫院藥房
• 零售藥局
• 網路藥局

第7章全球慢性骨髓性白血病治療市場，按地區，2020-2032 年，價值（十億美元）

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第8章競爭格局

• Teva Pharmaceutical Industries Ltd
• Hoffmann-La Roche Ltd.
• Novartis AG
• Sanofi
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Innovent Biologics, Inc.
• Viatris Inc.
• Lupin
• Million Health Pharmaceuticals
• Celon Labs
• Fresenius Kabi AG

第9章分析師建議

• 機會
• 分析師觀點
• Coherent Opportunity Map

第10章參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global Chronic Myeloid Leukemia Treatment Market is estimated to be valued at USD 9.04 Bn in 2025 and is expected to reach USD 14.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.

Figure. Chronic Myeloid Leukemia Treatment Market Share (%), By Region 2025

Chronic myeloid leukemia (CML) is a type of cancer that starts in the bone marrow and leads to an overproduction of white blood cells. The main driver of CML is a genetic abnormality that leads to unrestrained growth of myeloid cells in the bone marrow and their accumulation in the blood. If left untreated, CML progresses from a chronic phase to an accelerated phase and finally to a blast crisis. The global chronic myeloid leukemia treatment market has witnessed significant growth in recent times owing to the introduction of innovative targeted therapies such as tyrosine kinase inhibitors that have improved the clinical outcome and quality of life of CML patients.

Market Dynamics:

The global chronic myeloid leukemia treatment market is driven by the increasing prevalence of CML worldwide and growing awareness about early diagnosis and treatment. Moreover, the development and approval of novel targeted drugs with better efficacy and safety profiles compared to conventional chemotherapy have boosted the market growth. However, the high cost of targeted therapies remains a key challenge, especially in price-sensitive developing markets. On the positive side, increasing healthcare expenditure and demand for premium drugs provide lucrative opportunities for market players. Additionally, collaborations for clinical trials evaluating novel treatment approaches will further expand the market reach during the forecast period.

Key features of the study:

This report provides in-depth analysis of the global chronic myeloid leukemia treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic myeloid leukemia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc., Lupin, Million Health Pharmaceuticals, Celon Labs, and Fresenius Kabi AG

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global chronic myeloid leukemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic myeloid leukemia treatment market

Detailed Segmentation-

• Drug Type Insights
  • Tyrosine Kinase Inhibitors
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
  • Antimetabolites
  • Others
• Route of Administration Insights
  • Oral
  • Parenteral
  • Topical
  • Others (Nasal, etc.)
• Distribution Channel Insights
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
  • Teva Pharmaceutical Industries Ltd
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Innovent Biologics, Inc.
  • Viatris Inc.
  • Lupin
  • Million Health Pharmaceuticals
  • Celon Labs
  • Fresenius Kabi AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Chronic Myeloid Leukemia Treatment Market, By Drug Type
  • Chronic Myeloid Leukemia Treatment Market, By Route of Administration
  • Chronic Myeloid Leukemia Treatment Market, By Distribution Channel
  • Chronic Myeloid Leukemia Treatment Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Chronic Myeloid Leukemia Treatment Market, By Drug Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tyrosine Kinase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Imatinib (Gleevac)
• Dasatinib (Sprycel)
• Nilotinib (Tasigna)
• Bosutinib (Bosulif)
• Ponatinib (Iclusig)
• Asciminib (Scemblix)
• Others
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Chronic Myeloid Leukemia Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Nasal, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Chronic Myeloid Leukemia Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Myeloid Leukemia Treatment Market, By Region, 2020-2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Innovent Biologics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
• Lupin
• Million Health Pharmaceuticals
• Celon Labs
• Fresenius Kabi AG

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us